- Trial phase
- Approved
- Time to market
- Already on market since April 2000 (26+ years).
- Why 3/10
- Lantus is an already-approved, marketed drug with no pending PDUFA date, pivotal readout, or other hard binary catalyst scheduled. The next notable event is finalization of the October 2026 tentative antitrust settlement, but that is a legal/commercial outcome, not a regulatory binary. As a mature declining product within a large diversified pharma company, its share-price impact is limited.
Lantus has no upcoming FDA catalyst; the next event to watch is the finalization of the October 2026 tentative antitrust settlement with US wholesalers, which could involve a cash payment. More broadly, watch Sanofi's quarterly earnings for continued erosion of Lantus revenue as biosimilars (Semglee, LANGLARA) gain pharmacy shelf share. The real value story at Sanofi has shifted to Dupixent and newer launches, not Lantus.
Price Chart
Executive Summary
Lantus (insulin glargine) is Sanofi's long-acting basal insulin, first FDA-approved in April 2000. It generated roughly EUR 1.7 billion in 2025 revenue but is in structural decline as multiple interchangeable biosimilars (Semglee since 2021, LANGLARA since May 2026) erode market share. Sanofi recently reached a tentative settlement of US antitrust claims alleging improper patent listings to block competition. Lantus is a mature, declining cash-flow product within Sanofi's diversified portfolio; the company's growth is now driven by Dupixent, vaccines, and rare-disease drugs. There are no pending FDA catalysts for Lantus.
How It Works
Lantus is a long-acting insulin analog (insulin glargine) that provides a steady, 24-hour baseline level of insulin to control blood sugar in people with type 1 and type 2 diabetes. It is injected once daily under the skin and is designed to have no pronounced peak, mimicking the body's natural basal insulin release.
Trial Status
Lantus is a fully approved, commercially marketed product. No new pivotal trials are underway for the original formulation. Biosimilar competitors have completed their own clinical programs to gain FDA approval and interchangeability designations.
The Two-Sided Case
Upcoming Catalysts
- Finalization of the October 2026 tentative US antitrust settlement with drug wholesalers (financial terms not yet disclosed).
- Continued quarterly revenue erosion as interchangeable biosimilars (LANGLARA, Semglee) gain pharmacy-level substitution share.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Sanofi 6-K SNY ·Originating report